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INTRODUCTION:  Myotonic  dystrophy  of Steinert,  DM1,  is the  most  common  adult  muscular  dystrophy  and
generally  is  not  associated  to  development  on  multiple  site  neoplasm.  Von  Hippel-Lindau  (VHL)  disease is
a  dominantly  inherited  familial  cancer  syndrome  that is associated  to  tumors  such  as  hemangioblastoma
of  the  retina  or  central  nervous  system,  clear-cell  renal  carcinoma  (RCC)  and endocrine  tumors,  most
commonly  pheochromocytoma  and  non-secretory  pancreatic  islet  cell  cancers.  No data  exist  in literature
describing  the  coexistence  of both  DM1  and  VHL.
PRESENTATION OF  CASE:  Herein  we report  a case  of renal  and  pancreatic  neoplasm  in  a young  adult  female
affected  by  DM1  and  VHL  simultaneously.
DISCUSSION: DM1  is  due  to an  unstable  trinucleotide  (CTG)  expansion  in  the  30 antranslated  region  of  the
dystrophia  myotonica-protein  kinase  (DMPK)  gene,  located  on  chromosome  19q13.3.  Several  molecular
mechanisms  thought  to  be  determining  the classical  DM phenotype  have  been  shown.  VHL  disease  is
characterized  by marked  phenotypic  variability  and  the  most  common  tumors  are  hemangioblastomas
of  the  retina  or  central  nervous  system,  clear-cell  renal  carcinoma  (RCC)  and endocrine  tumors,  most
commonly  pheochromocytoma  and  non-secretory  pancreatic  islet  cell  cancers.  The  pancreatic  manifes-
tations  seen  in patients  with  VHL disease  are  divided  into  2 categories:  pancreatic  neuroendocrine  tumor
(PNET)  as  solid  tumors,  and  cystic  lesions,  including  a simple  cyst  and  serous  cystadenoma.  The surgical
approach  for  these  cistic  lesions  is to  consider  as  golden  standard.  Blansﬁeld  has  proposed  3 criteria  to
predict  metastatic  disease  of  PNET  in  patients  with  VHL  disease:  (1)  tumor  size  greater  than  or  equal  to
3  cm;  (2)  presence  of  a mutation  in  exon  3; and  (3)  tumor  doubling  time  less  than  500  d.  If the patient  has
none  of these  criteria  the  patient  could  be  followed  with  physical  examination  and  radiological  surveil-
lance  on  a 2/3  years  base.4 If the  patient  has 1 criterion,  the  patient  should  be  followed  more  closely  every
6  months  to 1 year.  If the  patient  has  2  or  3 criteria,  the  patient  should  be considered  for  surgery  given
the  high  risk  of  future  malignancy.  Our  patient  owned  only  one  criterion  but  in  presence  of  a second
malignant  tumor.  Our  hypothesis  for  this  rare ﬁndings  is  that  both  DM  and  VHL  might be derived  from
genetic  aberration  and these  might  be linked  to a major  cancer  susceptibility.  As far  as  we know  this  is
the  ﬁrst  conﬁrmed  case  of  RCC  and neuroendocrine  pancreatic  cancer  occurring  concurrently  with  VHL
and,  at  the  same  time,  DM1. According  to this  case  report  and  the  literature  data a VHL  should  be  ruled
out  in the  presence  of RCC  presenting  along  with  pancreatic  cysts/tumor.
CONCLUSION: As far as  we know  this  is  the  ﬁrst  conﬁrmed  case  of  RCC  and  neuroendocrine  pancreatic
cancer  occurring  concurrently  with  VHL  and,  at the  same  time,  DM1.  Our  hypothesis  for  the  unusual
ﬁndings  is  that both  DM  and  VHL  derived  from  genetic  aberration  and these  are  linked  to  a major  cancer
susceptibility.
gical © 2013 Sur
. IntroductionMyotonic dystrophy of Steinert, DM1, is the most common adult
uscular dystrophy.1
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Von Hippel–Lindau (VHL) disease is a dominantly inherited
familial cancer syndrome caused by mutations in the VHL tumor
suppressor gene.2
There are not previous data published that described the coex-
Open access under CC BY-NC-ND license. istence of the two neurological disorder mentioned above together
with a synchronous presence of pancreatic and renal cancer. Herein
we report a case of renal and pancreatic neoplasm in a young female
affected by DM1  and VHL simultaneously.
NC-ND license. 
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Fig. 3. Histology showing a neuroendocrine tumor (KI67 < 1%).CASE  REPORT
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. Case report
We  admitted to our ward a 27 years old woman for abdominal
ain. After several investigations, we raised the possibility of both
ancreatic neoplasm and right kidney cancer.
Her past medical history: DM1disagnosed 6 years before and
onﬁrmed by genetic which had showed an increased number of
TG trinucleotide repeats of greater than 200–400 in the DMPK
ene on chromosome 19q. The patient was known to have pancre-
tic cysts and in the 2009 underwent surgery for left RCC.
During  the last admission, a magnetic resonance of her abdomen
MRI) and a computed tomography (CT) (Figs. 1 and 2) of the
bdomen showed a pancreatic cyst, close to the pancreatic head,
uspicious for neoplasm and, right renal solid lesion also suspicious
or cancer.
Explorative laparotomy was performed and several biopsies
aken by the pancreatic cyst. Frozen extemporary section turned
ut to be positive for cancer cells, therefore a Whipple proce-
ure and wedge resections of the right renal neoplasm were
erformed.
The deﬁnitive histology report showed a pancreatic neuroen-
ocrine tumor (Ki67 < 1%, no vascular/neural invasion) (Fig. 3),
ithout limph nodes involvement and also showed renal clear cell
RCC) (Fig. 4). The coexistence of two different cancers in such
 young age brought us to perform a genetic assessment to rule
ut a VHL. Peripheral blood genetic analysis showed a germ line
rameshift mutation of the exon 1 of the VHL gene. Subsequently
 MRI  of the brain was performed showing a hemangioblastoma
f the oblonged medulla; non retinal involvement was  found and
he urinary cathecolamines was fpund to be within the normal
alue.
The postoperative period was remarkable and, upon improve-
ent, the patient was discharged 15 days after surgery. Six months
fter surgery, the patient was free of any signs of recurrence, and
he is still been followed up as an outpatient.
Fig. 1. MRI  of the abdomen showing an exophytic right kidney mass.
ig. 2. CT scan of the abdomen showing a pancreatic cyst in the head of the pancreas.Fig. 4. Histology showing clear renal cell carcinoma.
3. Discussion
DM1  is due to an unstable trinucleotide (CTG) expansion in the
30 antranslated region of the dystrophia myotonica-protein kinase
(DMPK) gene, located on chromosome 19q13.3. A broad range
of clinical features are variably seen including cardiac conduc-
tion defects, respiratory insufﬁciency, insulin-resistance, reduced
immunoglobulin levels, frontal balding, testicular atrophy, and
varying degrees of mental impairment.1,2 The DM1  disease is
caused by an increased number of CTG trinucleotide repeats of
greater than 50 in the myotonin protein kinase (DMPK) gene on
chromosome 19q. Several molecular mechanisms thought to be
determining the classical DM phenotype have been shown. One or
more of these may  play a role in the pathogenesis of tumor devel-
opment in DM patients, by dysregulating a critical pathway in a
tissue speciﬁc, time-dependent manner. A variety of benign and
malignant neoplasms have been described in DM1  but only one
case of renal clear cell cancer was  reported and no case regarding
the pancreatic neoplasm.1
VHL disease is characterized by marked phenotypic variabil-
ity and the most common tumors are hemangioblastomas of the
retina or central nervous system, clear-cell renal carcinoma (RCC)
and endocrine tumors, most commonly pheochromocytoma and
non-secretory pancreatic islet cell cancers.2
The pancreatic manifestations seen in patients with VHL disease
are divided into 2 categories: pancreatic neuroendocrine tumor
(PNET) as solid tumors, and cystic lesions, including a simple cyst
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nd serous cystadenoma.3 Cystic lesions complicated with VHL dis-
ase are generally asymptomatic and do not require any treatment.
t is necessary to differentiate them from other cystic tumor types,
uch as intraductal papillary mucin-producing tumors or muci-
ous cystic tumors, due to their malignant potential. The surgical
pproach for these cistic lesions is to consider as golden standard.3
Blansﬁeld has proposed 3 criteria to predict metastatic disease
f PNET in patients with VHL disease: (1) tumor size greater than
r equal to 3 cm;  (2) presence of a mutation in exon 3; and (3)
umor doubling time less than 500 d. If the patient has none of these
riteria the patient could be followed with physical examination
nd radiological surveillance on a 2/3 years base.4 If the patient
as 1 criterion, the patient should be followed more closely every 6
onths to 1 year. If the patient has 2 or 3 criteria, the patient should
e considered for surgery given the high risk of future malignancy.4
Our patient owned only one criterion but in presence of a second
alignant tumor.
RCC  is the most prevalent form of kidney cancer and is fre-
uently associated with loss of von Hippel–Lindau (VHL) gene
unction, resulting in the aberrant transcriptional activation of
enes that contribute to tumor growth and metastasis, including
ransforming growth factor-a (TGF-a), a ligand of the epidermal
rowth factor receptor (EGFR) tyrosine kinase.5
Lubensky et al. identiﬁed an allele loss in the VHL disease gene,
uggesting also that the VHL cancer gene is involved in pancreatic
ndocrine tumors that occur in VHL disease. However, the detailed
ole of the VHL gene within the cell is unclear and future analysis
f the gene should elucidate the pathology of VHL disease.6
Our hypothesis for this rare ﬁndings is that both DM and VHL
ight be derived from genetic aberration and these might be linkedo a major cancer susceptibility.1,2
As far as we know this is the ﬁrst conﬁrmed case of RCC and neu-
oendocrine pancreatic cancer occurring concurrently with VHL
nd, at the same time, DM1.
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According to this case report and the literature data a VHL should
be ruled out in the presence of RCC presenting along with pancreatic
cysts/tumor.
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